Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease,
Год журнала:
2024,
Номер
1871(3), С. 167637 - 167637
Опубликована: Дек. 23, 2024
With
few
viable
treatment
options,
glioblastoma
(GBM)
is
still
one
of
the
most
aggressive
and
deadly
types
brain
cancer.
Recent
developments
in
lipidomics
have
demonstrated
potential
lipid
metabolism
as
a
therapeutic
target
GBM.
The
thorough
examination
lipids
biological
systems,
or
lipidomics,
essential
to
comprehending
changed
profiles
found
GBM,
which
are
linked
tumor's
ability
grow,
survive,
resist
treatment.
use
drug
delivery
discovery
examined
this
study,
focusing
on
how
it
may
be
used
find
new
biomarkers,
create
multi-target
directed
ligands,
improve
systems.
We
also
cover
FDA-approved
medications,
clinical
trials
that
lipid-targeted
medicines,
integration
with
other
omics
technologies.
This
study
emphasizes
possible
tool
developing
more
effective
methods
for
GBM
by
exploring
various
lipid-centric
techniques.
Cancers,
Год журнала:
2024,
Номер
16(17), С. 2975 - 2975
Опубликована: Авг. 27, 2024
Malignant
gliomas
present
great
difficulties
in
treatment,
with
little
change
over
the
past
30
years
median
survival
time
of
15
months.
Current
treatment
options
include
surgery,
radiotherapy
(RT),
and
chemotherapy.
New
therapies
aimed
at
suppressing
formation
new
vasculature
(antiangiogenic
treatments)
or
destroying
formed
tumor
(vascular
disrupting
agents)
show
promise.
This
study
summarizes
existing
knowledge
regarding
processes
by
which
glioblastoma
(GBM)
tumors
acquire
resistance
to
antiangiogenic
treatments.
The
discussion
encompasses
activation
redundant
proangiogenic
pathways,
heightened
cell
invasion
metastasis,
induced
hypoxia,
creation
vascular
mimicry
channels,
regulation
immune
microenvironment.
Subsequently,
we
explore
potential
strategies
overcome
this
resistance,
such
as
combining
other
methods,
personalizing
treatments
for
each
patient,
focusing
on
therapeutic
targets,
incorporating
immunotherapy,
utilizing
drug
delivery
systems
based
nanoparticles.
Additionally,
would
like
discuss
limitations
methods
future
directions
enhance
beneficial
effects
patients
GBM.
Therefore,
review
aims
research
outcome
GBM
provide
a
more
promising
opportunity
thoroughly
exploring
mechanisms
investigating
novel
strategies.
Biomacromolecules,
Год журнала:
2024,
Номер
unknown
Опубликована: Сен. 11, 2024
Glioblastoma
multiforme
(GBM)
is
a
highly
malignant
brain
tumor
with
poor
prognosis
and
limited
treatment
options.
Drug
delivery
by
stimuli-responsive
nanocarriers
holds
great
promise
for
improving
the
modalities
of
GBM.
At
beginning
review,
we
highlighted
stimuli-active
polymeric
carrying
therapies
that
potentially
boost
anti-GBM
responses
employing
endogenous
(pH,
redox,
hypoxia,
enzyme)
or
exogenous
stimuli
(light,
ultrasonic,
magnetic,
temperature,
radiation)
as
triggers
controlled
drug
release
mainly
via
hydrophobic/hydrophilic
transition,
degradability,
ionizability,
etc.
Modifying
these
target
ligands
further
enhanced
their
capacity
to
traverse
blood-brain
barrier
(BBB)
preferentially
accumulate
in
glioma
cells.
These
unique
features
lead
more
effective
cancer
minimal
adverse
reactions
superior
therapeutic
outcomes.
Finally,
review
summarizes
existing
difficulties
future
prospects
treating
Overall,
this
offers
theoretical
guidelines
developing
intelligent
versatile
facilitate
precise
GBM
clinical
settings.
Journal of Integrative Neuroscience,
Год журнала:
2025,
Номер
24(3)
Опубликована: Март 21, 2025
Radiotherapy
is
one
of
the
primary
modalities
for
oncologic
treatment
and
has
been
utilized
at
least
once
in
over
half
newly
diagnosed
cancer
patients.
Cranial
radiotherapy
significantly
enhanced
long-term
survival
rates
patients
with
brain
tumors.
However,
radiation-induced
injury,
particularly
hippocampal
neuronal
damage
along
impairment
neurogenesis,
inflammation,
gliosis,
adversely
affects
quality
life
these
Astrocytes,
a
type
glial
cell
that
are
abundant
brain,
play
essential
roles
maintaining
homeostasis
function.
Despite
their
importance,
pathophysiological
changes
astrocytes
induced
by
radiation
have
not
thoroughly
investigated,
no
systematic
or
comprehensive
review
addressing
effects
on
related
diseases
conducted.
In
this
paper,
we
current
studies
neurophysiological
following
exposure.
We
describe
astrocytes,
including
astrogliosis,
astrosenescence,
associated
cellular
molecular
mechanisms.
Additionally,
summarize
impairments
neurogenesis
blood-brain
barrier
(BBB).
Based
research,
propose
may
serve
as
potential
therapeutic
targets
treating
injury
(RIBI)
subsequent
neurological
neuropsychiatric
disorders.
This
study
aimed
to
develop
and
validate
a
predictive
model
for
early
recurrence
of
high-grade
glioma
(HGG)
within
180
days,
assess
the
prognostic
value
preoperative
postoperative
temporalis
muscle
metrics
(area
thickness),
explore
their
significance
in
follow-up.
Seventy-one
molecularly
confirmed
HGG
patients
were
included,
with
data
sourced
from
local
TCIA
(The
Cancer
Imaging
Archive)
RHUH-GBM
(Río
Hortega
University
Hospital
Glioblastoma)
dataset.
Tumor
segmentation
was
performed
using
deep
learning,
radiomic
features
extracted
following
comparison
manual
segmentation.
Feature
selection
conducted
mutual
information
recursive
feature
elimination.
A
comprehensive
integrating
3D
tumor
radiomics
developed
compared
tumor-only
identify
optimal
framework.
SHAP
analysis
used
evaluate
interpretability
importance.
The
TM_Tumor_HistGradientBoosting
model,
incorporating
16
including
metrics,
outperformed
accuracy
(0.89),
recall
(0.87),
F1
score
(0.88).
highlighted
that
cross-sectional
area
strongly
associated
risk,
while
thickness
significantly
contributed
prediction.
Combining
MRI
substantially
improved
prediction
HGG.
Temporalis
serve
as
objective
sustainable
indicators
significant
clinical
Objective
In
order
to
establish
a
connection
between
programmed
death-ligand
1
(PD-L1)
expression
and
glioma
grades
as
well
the
presence
of
IDH1
mutations,
it
is
necessary
investigate
PD-L1
isocitrate
dehydrogenase-1
(IDH1)
in
patients
assess
their
potential
predictive
markers
for
glioblastoma
multiforme
(GBM)
immunotherapy.
We
analyzed
frequency
samples.
Methodology
this
two-year
retrospective
study,
45
cases
varying
(grades
2
4)
were
examined
at
tertiary
care
hospital.
Tumor
samples
that
formalin-fixed,
paraffin-embedded
(FFPE)
obtained
from
pathology
archives
According
WHO
Classification
Central
Nervous
System
Tumors,
5th
edition,
tumor
grading
histopathological
subtyping
carried
out.
antibody
(clone
28-8)
(R132H,
clone
QM002,
Quartett
Immunodiagnostika,
1:100
dilution)
used
immunohistochemistry
(IHC).
The
sections
underwent
deparaffinization,
rehydration,
antigen
retrieval
using
Leica
bond
III
staining
platform.
Based
on
proportion
score
(TPS),
which
viable
cells
with
membranous
staining,
was
assessed.
literature's
standardized
cut-off
values
determine
positive
expression.
Staining
intensity
cell
location
status
mutations.
Age,
sex,
among
clinical
demographic
information
gathered
about
patient.
association
expression,
grades,
(R132H)
mutation
assessed
statistically
SPSS
software
Chi-square
test.
threshold
statistical
significance
p
<
0.05.
For
every
IHC
run,
negative
controls
part
quality
control
procedures.
To
reduce
bias
guarantee
consistency,
two
pathologists
post
graduate
residents
independently
reviewed
results.
Results
found
27
out
36
(75%)
grade
4
six
nine
(66.7%)
gliomas.
Overall,
33/45
(73.3%)
gliomas
had
However,
did
not
correlate
significant
way.
be
inversely
correlated
(p
0.05).
Conclusion
findings
suggest
may
promising
therapeutic
target,
even
absence
grade-specific
trends
by
demonstrating
majority
cases,
highlighting
its
target
GBM
results
provide
insight
into
immune
landscape
pave
way
future
research
effective
combination
therapies
GBM,
despite
lack
correlation
Current Issues in Molecular Biology,
Год журнала:
2024,
Номер
46(9), С. 9881 - 9894
Опубликована: Сен. 5, 2024
The
race
to
find
an
effective
treatment
for
glioblastoma
(GBM)
remains
a
critical
topic,
because
of
its
high
aggressivity
and
impact
on
survival
the
quality
life.
Currently,
due
GBM's
heterogeneity,
conventional
success
rate
response
therapy
are
relatively
low,
with
median
less
than
20
months.
A
new
point
view
can
be
provided
by
comprehension
tumor
microenvironment
(TME)
in
pursuance
development
therapeutic
strategies
aim
longer
improved
life
disease-free
interval
(DFI).
main
components
GBM
TME
represented
extracellular
matrix
(ECM),
glioma
cells
stem
(GSCs),
immune
(microglia,
macrophages,
neutrophils,
lymphocytes),
neuronal
cells,
all
them
having
dynamic
interactions
being
able
influence
tumoral
growth,
progression,
drug
resistance
thus
potential
target.
This
paper
will
review
latest
research
targets
form
up-to-date
strategy.
